For a better experience, Read this story in our App
TO ENJOY ADDITIONAL BENEFITS
Connect With Us
Get BusinessLine apps on
Built on fee-based model, Welcure Drugs & Pharmaceuticals will earn fixed 5% commission on the cost of goods.
Welcure Drugs & Pharmaceuticals has signed a definitive mandate with Thailand-based Fortune Sagar Impex Company for third-party sourcing and procurement services.
The mandate, valued at ₹517 crore, is structured under an ex-works model and represents a significant milestone in Welcure’s service-led growth strategy.
As per the mandate, Welcure Drugs & Pharmaceuticals Ltd will engage in sourcing and procurement of multiple finished-dosage SKUs. Built on fee-based model, the company will earn fixed 5 per cent commission on the cost of goods. The estimated service income of ₹26 crore is expected in FY26, said the company.
The mandate enhances Welcure’s fee-based portfolio without incremental balance-sheet exposure, making this a high-margin growth opportunity, it added.
The buyer, Fortune Sagar Impex Company, Thailand, will be in-charge of responsibilities related to packaging, labelling, containerisation, insurance, freight and all destination-country regulatory clearances.
Published on June 18, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.